You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

RITALIN LA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ritalin La, and what generic alternatives are available?

Ritalin La is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ritalin La

A generic version of RITALIN LA was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RITALIN LA?
  • What are the global sales for RITALIN LA?
  • What is Average Wholesale Price for RITALIN LA?
Drug patent expirations by year for RITALIN LA
Drug Prices for RITALIN LA

See drug prices for RITALIN LA

Drug Sales Revenue Trends for RITALIN LA

See drug sales revenues for RITALIN LA

Recent Clinical Trials for RITALIN LA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johns Hopkins UniversityPhase 4
University of FloridaEarly Phase 1
University of ZurichPhase 1

See all RITALIN LA clinical trials

Pharmacology for RITALIN LA
Paragraph IV (Patent) Challenges for RITALIN LA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RITALIN LA Extended-release Capsules methylphenidate hydrochloride 10 mg 021284 1 2007-05-21
RITALIN LA Extended-release Capsules methylphenidate hydrochloride 20 mg, 30 mg and 40 mg 021284 2006-08-21

US Patents and Regulatory Information for RITALIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-004 Apr 10, 2004 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-003 Jun 5, 2002 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-001 Jun 5, 2002 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-002 Jun 5, 2002 AB1 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-005 Oct 27, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RITALIN LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-004 Apr 10, 2004 ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-002 Jun 5, 2002 ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-004 Apr 10, 2004 ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-003 Jun 5, 2002 ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-002 Jun 5, 2002 ⤷  Sign Up ⤷  Sign Up
Sandoz RITALIN LA methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021284-003 Jun 5, 2002 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RITALIN LA

See the table below for patents covering RITALIN LA around the world.

Country Patent Number Title Estimated Expiration
Japan 5463223 ⤷  Sign Up
Mexico 2007016151 COMPOSICIONES DE LIBERACION CONTROLADA Y EN FORMA DE NANO-PARTICULAS QUE COMPRENDEN COMPUESTOS ARIL-HETEROCICLICOS. (NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING ARYL-HETEROCYCLIC COMPOUNDS.) ⤷  Sign Up
New Zealand 511442 Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl ⤷  Sign Up
Japan 2009541359 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2006132752 ⤷  Sign Up
European Patent Office 1126826 COMPOSITION DE METHYLPHENIDATE A LIBERATION MODIFIEE MULTIPARTICULAIRE (MULTIPARTICULATE MODIFIED RELEASE COMPOSITION OF METHYLPHENIDATE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.